Fusion imaging guidance for endovascular recanalization of peripheral occlusive disease.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
02 2022
Historique:
received: 30 12 2020
accepted: 29 07 2021
pubmed: 8 9 2021
medline: 24 2 2022
entrez: 7 9 2021
Statut: ppublish

Résumé

Endovascular procedures are now the first line option for treatment of lower extremity arterial disease. Fusion imaging guidance has been reported to reduce radiation exposure and reintervention rates during fenestrated and branched endovascular repairs, but limited literature exists on its benefits during lower extremity arterial disease endovascular procedures, and more specifically peripheral occlusive disease (POD). This study aims to evaluate the radiation exposure and technical success benefits of fusion imaging guidance in a large cohort of patients treated endovascularly for complex POD. From January 2017 to September 2019, in a single center, all consecutive patients presenting symptomatic occlusions (Rutherford Baker categories 3 to 6) in the setting of POD and treated endovascularly were retrospectively assessed for inclusion. All procedures were performed under augmented fluoroscopy guidance (Vessel ASSIST, GE Healthcare), overlaying on live imaging the 3D path for transluminal recanalization based on the preoperative computed tomography angiography. Technical success, dose area product (DAP), total cumulated air kerma (CAK), and fluoroscopy time were collected. DAP results were compared with the literature. During the study period, 179 patients were treated for iliac (n = 56) or femoropopliteal (n = 123) symptomatic arterial occlusions. Technical success was reported in 171 of 179 procedures (95.5%). The use of a re-entry catheter was required to achieve technical success in 11 patients (6.1%). Mean DAP and CAK were 12.70 Gy·cm Routine use of fusion imaging guidance during POD endovascular treatment is associated with low radiation exposure, high technical success, and reduced need for re-entry systems.

Identifiants

pubmed: 34492289
pii: S0741-5214(21)01983-2
doi: 10.1016/j.jvs.2021.07.239
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

610-617

Informations de copyright

Copyright © 2021 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Justine Mougin (J)

Centre Vasculaire, Groupe Hospitalier Paris Saint Joseph, Paris, France.

Nicolas Louis (N)

Chirurgie Vasculaire, Clinique Les Franciscaines, Nîmes, France.

Eric Maupas (E)

Chirurgie Vasculaire, Clinique Les Franciscaines, Nîmes, France.

Yann Goueffic (Y)

Centre Vasculaire, Groupe Hospitalier Paris Saint Joseph, Paris, France.

Dominique Fabre (D)

Centre Vasculaire, Groupe Hospitalier Paris Saint Joseph, Paris, France.

Stéphan Haulon (S)

Centre Vasculaire, Groupe Hospitalier Paris Saint Joseph, Paris, France. Electronic address: haulon@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH